PKTX
ProtoKinetix, Incorporated0.0048
+0.0006+14.3%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
No earnings call transcript available
Key Stats
Market Cap
1.88MP/E (TTM)
-Basic EPS (TTM)
0.00Dividend Yield
0%Recent Filings
8-K
CEO shift after leader's passing
ProtoKinetix disclosed the sudden passing of former leader Clarence Smith, with new CEO Michael Guzzetta vowing to advance the AAGP® (PKX-001) glycopeptide platform. The robust molecule, backed by a stable global patent portfolio, draws pharma interest for Type 1 Diabetes, cell therapy, and ophthalmological uses. Leadership transitions test continuity. Forward-looking statements carry risks.
10-Q
Q3 FY2025 results
ProtoKinetix posted a Q3 net loss of $84,906, nearly flat y/y from $84,573, while nine-month loss widened to $273,663 from $261,676 on higher professional fees and R&D. Cash burn eased, with operating cash use at $135,935 (nine months, derived) versus $177,808 y/y, fueled by payables growth. Cash ticked up to $607 from negative at year-start, propped by $177,500 in private placements; no debt. Intangibles hit $475,966 after $44,371 additions. Stockholders approved extra shares post-quarter. Cash won't last. Effects of competition loom.
8-K
Authorized shares increased
ProtoKinetix boosted its authorized common shares from 500 million to 600 million via stockholder consent, effective October 6, 2025, after 57.1% approval from 222 million votes cast. This expands flexibility for potential equity raises. Stockholders acted swiftly by deadline. No specific use or risks detailed.
10-Q
Q2 FY2025 results
ProtoKinetix posted a Q2 net loss of $91,067, up 7% y/y from $85,076, driven by higher professional fees and R&D outlays amid ongoing AAGP molecule validation. For the half-year, losses widened to $188,757 from $177,103 y/y, with operating expenses climbing on auditing and consulting costs, while amortization edged up 5% y/y to $25,548. Cash dwindled to $112 at quarter-end, propped by $167,500 in private placements, yet net operating cash burn held steady at $132,027 for the period. Intangible assets grew to $473,255 after $29,019 in patent additions. Stock issuances added 17.2 million shares. Funding remains tight. Competition in biotech stalls progress.
10-Q
Q1 FY2025 results
ProtoKinetix posted a Q1 net loss of $97,690, up 6.1% y/y from $92,026, driven by higher professional fees for auditing and legal work while research and development dipped 7.7% to $33,810 amid cost-sharing pursuits. Operating expenses totaled $97,690, matching the net loss with no revenue or other items; diluted EPS held at $(0.00) on 374.1 million weighted shares, anti-dilutive options excluded. Cash climbed to $49,477 from a negative balance, fueled by $132,000 in private placements against $51,970 operating outflow and $25,856 patent investments. Intangibles grew to $478,098 after $20,976 additions. Investors back the AAGP push. Yet competition shadows biotech validation.
AGTX
Agentix Corp.
0.04+0.00
AURX
Nuo Therapeutics, Inc.
2.00-0.15
ONCO
Onconetix, Inc.
1.94-0.04
PPCB
Propanc Biopharma, Inc.
0.73-0.03
PROK
ProKidney Corp.
2.20+0.12
PTGX
Protagonist Therapeutics, Inc.
91.54-3.25
PTIX
Protagenic Therapeutics, Inc.
1.52-0.07
PVCT
Provectus Biopharmaceuticals, I
0.06+0.00
RCKT
Rocket Pharmaceuticals, Inc.
3.43+0.02
RMTG
Regenerative Medical Technology
0.04+0.00